Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 41,317 | 59,557 | 51,540 | 39,864 | 50,817 |
| Marketable Securities | 203,669 | 228,652 | 188,590 | 235,863 | 263,205 |
| Receivables | 25,347 | 36,451 | 25,126 | 9,303 | 8,175 |
| Inventories | 8,369 | 7,782 | 8,738 | 7,270 | 5,212 |
| TOTAL | $284,896 | $338,863 | $281,436 | $303,860 | $334,295 |
| Non-Current Assets | |||||
| PPE Net | 2,465 | 1,209 | 1,075 | 1,075 | 1,066 |
| Investments And Advances | 23,053 | 13,645 | 13,374 | 11,939 | 5,307 |
| Intangibles | 14,452 | 14,729 | 12,972 | 7,241 | 7,371 |
| Other Non-Current Assets | 2,786 | 4,357 | 4,615 | 3,203 | 3,114 |
| TOTAL | $42,756 | $33,940 | $32,036 | $23,458 | $16,858 |
| Total Assets | $327,652 | $372,803 | $313,472 | $327,318 | $351,153 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 37,948 | 49,768 | 44,264 | 27,009 | 22,841 |
| Other current liabilities | 609 | 526 | 746 | 540 | 557 |
| TOTAL | $39,145 | $50,877 | $45,599 | $27,622 | $23,440 |
| Non-Current Liabilities | |||||
| Long Term Debt | 168,514 | 168,273 | 71,959 | 69,383 | 69,383 |
| Other Non-Current Liabilities | 5,735 | 5,998 | 3,593 | 1,339 | 1,532 |
| TOTAL | $174,249 | $174,271 | $75,552 | $70,722 | $70,915 |
| Total Liabilities | $213,394 | $225,148 | $121,151 | $98,344 | $94,355 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 99,297 | 98,849 | 98,826 | 98,214 | 98,120 |
| Common Shares | 10 | 10 | 10 | 10 | 10 |
| Retained earnings | -294,603 | -253,279 | -202,128 | -157,245 | -123,305 |
| Other shareholders' equity | 125 | -7 | -46 | 72 | 220 |
| TOTAL | $114,258 | $147,655 | $192,321 | $228,974 | $256,798 |
| Total Liabilities And Equity | $327,652 | $372,803 | $313,472 | $327,318 | $351,153 |